The coronavirus outbreak has subsided significantly, as the end of 2021 is nearing. This outbreak led to several developments in the healthcare industry, especially in the vaginal panel testing market in EMEA. The trend of home testing has benefitted healthcare companies within the market landscape. This is why manufacturers are tapping revenue opportunities through eCommerce to expand their revenue streams.
Since manufacturers witnessed supply shortage for laboratory items during the peak pandemic period, companies in the vaginal panel testing market in EMEA are increasing efforts to maintain optimum inventory levels. Surge in spending capacity of individuals and relaxation of COVID-19 restrictions across countries is contributing toward the increase in overall revenue flow in the market.
Companies are increasing the production of molecular nucleic acid amplification tests (NAAT) to support the detection of vaginitis and vaginosis. The high prevalence of candida vaginitis, trichomoniasis, and bacterial vaginosis (BV) among women has led to innovations in assays. Manufacturers are increasing the availability of vaginitis panels that aid in the detection of yeast infections and trichomoniasis.
The vaginal panel testing market in EMEA is projected to cross US$ 175 Mn by 2031. Companies are increasing R&D in assays that enable better guided drug treatment, reduced suffering in affected women, and fewer recurrent doctor’s office visits. Such assays are helping healthcare companies to advance in molecular testing.
The vaginal panel testing market in EMEA is slated to clock a CAGR of 3.9% during the forecast period. Nevertheless, intensified competition in the market is challenging companies to develop an assay portfolio that caters to both sexual and vaginal health, which includes vaginitis testing alongside comprehensive sexually transmitted infections (STIs) and viral load testing.
There is a growing demand for vaginal panels that provide the flexibility to detect several infections and disease states with only one vaginal swab, which includes gonorrhea and candida species. Since the CDC (Centers for Disease Control and Prevention) is recommending the testing of trichomonas vaginalis (TV) in all women seeking treatment for vaginal discharge, such findings are leading to product sales.
Privacy and convenience are becoming important factors in the vaginal panel testing market in EMEA. This has led to innovations in affordable at-home testing products. Manufacturers in the vaginal panel testing market in EMEA are boosting the production of lab certified vaginal panels that help to generate results in less than five days. Since many women are concerned for unusual changes in the color, odor, and texture of vaginal discharge, at-home vaginal panel testing products are providing them several advantages.
At-home vaginal panel testing products eliminate the need of awkward conversations with peers and physicians, and help to screen common causes of abnormal vaginal discharge at comfort of the home.
Molecular testing using a DNA probe for the detection of candida species and gardnerella vaginalis is growing prominent in the vaginal panel testing market in EMEA. Companies are increasing research in this space, since vaginitis accounts for several doctor office visits each year. Since the complications of BV can be significant in pregnant women, manufacturers are boosting output capacities in vaginal panel testing products.
In order to boost credibility, companies in the vaginal panel testing market in EMEA are increasing the availability of FDA-authorized products. These include polymerase chain reaction (PCR) assay and microbiome-based vaginal panel tests. Companies are innovating in assays that support antimicrobial resistance initiatives in women by detecting the presence of Candida krusei and C. glabrata.
Analysts’ Viewpoint
Affordable at-home testing trends are creating revenue opportunities for companies in the vaginal panel testing market in EMEA in eCommerce during the post coronavirus period. Since traditional diagnostic techniques tend to be subjective with variable sensitivity and specificity, healthcare companies are capitalizing on this opportunity to innovate in vaginal panels. However, a negative test result done with vaginitis panel testing by DNA direct probe does not rule out the presence of microorganisms below the test sensitivity. Hence, companies should increase awareness about using vaginitis panel testing by DNA direct probe with vaginal specimens to improve medical outcomes. There is a growing demand for products that reduce repeated doctor visits and improve antimicrobial stewardship.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 117.5 Mn |
|
Market Forecast Value in 2031 |
US$ 175 Mn |
|
Growth Rate (CAGR) |
3.9% |
|
Forecast Period |
2021–2031 |
|
Historical Data Available for |
2017–2019 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross segment analysis at as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
Europe and Middle East & Africa Vaginal Panel Testing Market – Segmentation
TMR’s study on the vaginal panel testing market in EMEA includes information divided into four segments: type, application, end-user, and region. Changing industry trends and other market dynamics associated with these segments of the vaginal panel testing market in EMEA are discussed in detail.
| Type |
|
| Application |
|
| End-user |
|
| Region |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe and Middle East & Africa Vaginal Panel Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.2. Technological Advancements
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long-term impact)
6. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2018–2030
6.3.1. Direct Molecular DNA Probe
6.3.2. Molecular Nucleic Acid Amplification Test (NAAT)
6.4. Market Attractiveness Analysis, by Type
7. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2018–2030
7.3.1. Bacterial Vaginosis
7.3.2. Vulvovaginal Candidiasis
7.3.3. Chlamydia
7.3.4. Gonorrhoea
7.3.5. Trichomoniasis
7.3.6. Others
7.4. Market Attractiveness Analysis, by Application
8. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2018–2030
8.3.1. Hospitals
8.3.2. Diagnostic Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. Europe
9.2.2. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. Europe Vaginal Panel Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2018–2030
10.2.1. Direct molecular Direct Molecular DNA Probe
10.2.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.3. Market Value Forecast, by Application, 2018–2030
10.3.1. Bacterial Vaginosis
10.3.2. Vulvovaginal Candidiasis
10.3.3. Chlamydia
10.3.4. Gonorrhoea
10.3.5. Trichomoniasis
10.3.6. Others
10.4. Market Value Forecast, by End-user, 2018–2030
10.4.1. Hospitals
10.4.2. Diagnostic Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2018–2030
10.5.1. Germany
10.5.1.1. Market Value Forecast, by Type, 2017–2031
10.5.1.1.1. Polymerase Chain Reaction (PCR) Assay
10.5.1.1.2. Direct Molecular DNA Probe
10.5.1.1.3. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.1.2. Market Value Forecast, by Application, 2017–2031
10.5.1.2.1. Bacterial Vaginosis
10.5.1.2.2. Vulvovaginal Candidiasis
10.5.1.2.3. Chlamydia
10.5.1.2.4. Gonorrhoea
10.5.1.2.5. Trichomoniasis
10.5.1.2.6. Others
10.5.1.3. Market Value Forecast, by End-user, 2017–2031
10.5.1.3.1. Hospital
10.5.1.3.2. Diagnostic Centers
10.5.1.3.3. Others
10.5.2. U.K.
10.5.2.1. Market Value Forecast, by Type, 2017–2031
10.5.2.1.1. Polymerase Chain Reaction (PCR) Assay
10.5.2.1.2. Direct Molecular DNA Probe
10.5.2.1.3. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.2.2. Market Value Forecast, by Application, 2017–2031
10.5.2.2.1. Bacterial Vaginosis
10.5.2.2.2. Vulvovaginal Candidiasis
10.5.2.2.3. Chlamydia
10.5.2.2.4. Gonorrhoea
10.5.2.2.5. Trichomoniasis
10.5.2.2.6. Others
10.5.2.3. Market Value Forecast, by End-user, 2017–2031
10.5.2.3.1. Hospital
10.5.2.3.2. Diagnostic Centers
10.5.2.3.3. Others
10.5.3. France
10.5.3.1. Market Value Forecast, by Type, 2017–2031
10.5.3.1.1. Direct Molecular DNA Probe
10.5.3.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.3.2. Market Value Forecast, by Application, 2017–2031
10.5.3.2.1. Bacterial Vaginosis
10.5.3.2.2. Vulvovaginal Candidiasis
10.5.3.2.3. Chlamydia
10.5.3.2.4. Gonorrhoea
10.5.3.2.5. Trichomoniasis
10.5.3.2.6. Others
10.5.3.3. Market Value Forecast, by End-user, 2017–2031
10.5.3.3.1. Hospital
10.5.3.3.2. Diagnostic Centers
10.5.3.3.3. Others
10.5.4. Italy
10.5.4.1. Market Value Forecast, by Type, 2017–2031
10.5.4.1.1. Direct Molecular DNA Probe
10.5.4.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.4.2. Market Value Forecast, by Application, 2017–2031
10.5.4.2.1. Bacterial Vaginosis
10.5.4.2.2. Vulvovaginal Candidiasis
10.5.4.2.3. Chlamydia
10.5.4.2.4. Gonorrhoea
10.5.4.2.5. Trichomoniasis
10.5.4.2.6. Others
10.5.4.3. Market Value Forecast, by End-user, 2017–2031
10.5.4.3.1. Hospital
10.5.4.3.2. Diagnostic Centers
10.5.4.3.3. Others
10.5.5. Spain
10.5.5.1. Market Value Forecast, by Type, 2017–2031
10.5.5.1.1. Direct Molecular DNA Probe
10.5.5.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.5.2. Market Value Forecast, by Application, 2017–2031
10.5.5.2.1. Bacterial Vaginosis
10.5.5.2.2. Vulvovaginal Candidiasis
10.5.5.2.3. Chlamydia
10.5.5.2.4. Gonorrhoea
10.5.5.2.5. Trichomoniasis
10.5.5.2.6. Others
10.5.5.3. Market Value Forecast, by End-user, 2017–2031
10.5.5.3.1. Hospital
10.5.5.3.2. Diagnostic Centers
10.5.5.3.3. Others
10.5.6. Sweden
10.5.6.1. Market Value Forecast, by Type, 2017–2031
10.5.6.1.1. Direct Molecular DNA Probe
10.5.6.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.6.2. Market Value Forecast, by Application, 2017–2031
10.5.6.2.1. Bacterial Vaginosis
10.5.6.2.2. Vulvovaginal Candidiasis
10.5.6.2.3. Chlamydia
10.5.6.2.4. Gonorrhoea
10.5.6.2.5. Trichomoniasis
10.5.6.2.6. Others
10.5.6.3. Market Value Forecast, by End-user, 2017–2031
10.5.6.3.1. Hospital
10.5.6.3.2. Diagnostic Centers
10.5.6.3.3. Others
10.5.7. Denmark
10.5.7.1. Market Value Forecast, by Type, 2017–2031
10.5.7.1.1. Direct Molecular DNA Probe
10.5.7.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.7.2. Market Value Forecast, by Application, 2017–2031
10.5.7.2.1. Bacterial Vaginosis
10.5.7.2.2. Vulvovaginal Candidiasis
10.5.7.2.3. Chlamydia
10.5.7.2.4. Gonorrhoea
10.5.7.2.5. Trichomoniasis
10.5.7.2.6. Others
10.5.7.3. Market Value Forecast, by End-user, 2017–2031
10.5.7.3.1. Hospital
10.5.7.3.2. Diagnostic Centers
10.5.7.3.3. Others
10.5.8. Finland
10.5.8.1. Market Value Forecast, by Type, 2017–2031
10.5.8.1.1. Direct Molecular DNA Probe
10.5.8.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.8.2. Market Value Forecast, by Application, 2017–2031
10.5.8.2.1. Bacterial Vaginosis
10.5.8.2.2. Vulvovaginal Candidiasis
10.5.8.2.3. Chlamydia
10.5.8.2.4. Gonorrhoea
10.5.8.2.5. Trichomoniasis
10.5.8.2.6. Others
10.5.8.3. Market Value Forecast, by End-user, 2017–2031
10.5.8.3.1. Hospital
10.5.8.3.2. Diagnostic Centers
10.5.8.3.3. Others
10.5.9. Austria
10.5.9.1. Market Value Forecast, by Type, 2017–2031
10.5.9.1.1. Direct Molecular DNA Probe
10.5.9.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.9.2. Market Value Forecast, by Application, 2017–2031
10.5.9.2.1. Bacterial Vaginosis
10.5.9.2.2. Vulvovaginal Candidiasis
10.5.9.2.3. Chlamydia
10.5.9.2.4. Gonorrhoea
10.5.9.2.5. Trichomoniasis
10.5.9.2.6. Others
10.5.9.3. Market Value Forecast, by End-user, 2017–2031
10.5.9.3.1. Hospital
10.5.9.3.2. Diagnostic Centers
10.5.9.3.3. Others
10.5.10. Switzerland
10.5.10.1. Market Value Forecast, by Type, 2017–2031
10.5.10.1.1. Direct Molecular DNA Probe
10.5.10.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.10.2. Market Value Forecast, by Application, 2017–2031
10.5.10.2.1. Bacterial Vaginosis
10.5.10.2.2. Vulvovaginal Candidiasis
10.5.10.2.3. Chlamydia
10.5.10.2.4. Gonorrhoea
10.5.10.2.5. Trichomoniasis
10.5.10.2.6. Others
10.5.10.3. Market Value Forecast, by End-user, 2017–2031
10.5.10.3.1. Hospital
10.5.10.3.2. Diagnostic Centers
10.5.10.3.3. Others
10.5.11. Benelux
10.5.11.1. Market Value Forecast, by Type, 2017–2031
10.5.11.1.1. Direct Molecular DNA Probe
10.5.11.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.11.2. Market Value Forecast, by Application, 2017–2031
10.5.11.2.1. Bacterial Vaginosis
10.5.11.2.2. Vulvovaginal Candidiasis
10.5.11.2.3. Chlamydia
10.5.11.2.4. Gonorrhoea
10.5.11.2.5. Trichomoniasis
10.5.11.2.6. Others
10.5.11.3. Market Value Forecast, by End-user, 2017–2031
10.5.11.3.1. Hospital
10.5.11.3.2. Diagnostic Centers
10.5.11.3.3. Others
10.5.12. Norway
10.5.12.1. Market Value Forecast, by Type, 2017–2031
10.5.12.1.1. Direct Molecular DNA Probe
10.5.12.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.12.2. Market Value Forecast, by Application, 2017–2031
10.5.12.2.1. Bacterial Vaginosis
10.5.12.2.2. Vulvovaginal Candidiasis
10.5.12.2.3. Chlamydia
10.5.12.2.4. Gonorrhoea
10.5.12.2.5. Trichomoniasis
10.5.12.2.6. Others
10.5.12.3. Market Value Forecast, by End-user, 2017–2031
10.5.12.3.1. Hospital
10.5.12.3.2. Diagnostic Centers
10.5.12.3.3. Others
10.5.13. Poland
10.5.13.1. Market Value Forecast, by Type, 2017–2031
10.5.13.1.1. Direct Molecular DNA Probe
10.5.13.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.13.2. Market Value Forecast, by Application, 2017–2031
10.5.13.2.1. Bacterial Vaginosis
10.5.13.2.2. Vulvovaginal Candidiasis
10.5.13.2.3. Chlamydia
10.5.13.2.4. Gonorrhoea
10.5.13.2.5. Trichomoniasis
10.5.13.2.6. Others
10.5.13.3. Market Value Forecast, by End-user, 2017–2031
10.5.13.3.1. Hospital
10.5.13.3.2. Diagnostic Centers
10.5.13.3.3. Others
10.5.14. Rest of Europe
10.5.14.1. Market Value Forecast, by Type, 2017–2031
10.5.14.1.1. Direct Molecular DNA Probe
10.5.14.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
10.5.14.2. Market Value Forecast, by Application, 2017–2031
10.5.14.2.1. Bacterial Vaginosis
10.5.14.2.2. Vulvovaginal Candidiasis
10.5.14.2.3. Chlamydia
10.5.14.2.4. Gonorrhoea
10.5.14.2.5. Trichomoniasis
10.5.14.2.6. Others
10.5.14.3. Market Value Forecast, by End-user, 2017–2031
10.5.14.3.1. Hospital
10.5.14.3.2. Diagnostic Centers
10.5.14.3.3. Others
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Middle East & Africa Vaginal Testing Panels Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Direct Molecular DNA Probe
11.2.2. Molecular Nucleic Acid Amplification Test (NAAT)
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Bacterial Vaginosis
11.3.2. Vulvovaginal Candidiasis
11.3.3. Chlamydia
11.3.4. Gonorrhoea
11.3.5. Trichomoniasis
11.3.6. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospital
11.4.2. Diagnostic Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. GCC Countries
11.5.1.1. Market Value Forecast, by Type, 2017–2031
11.5.1.1.1. Direct Molecular DNA Probe
11.5.1.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
11.5.1.2. Market Value Forecast, by Application, 2017–2031
11.5.1.2.1. Bacterial Vaginosis
11.5.1.2.2. Vulvovaginal Candidiasis
11.5.1.2.3. Chlamydia
11.5.1.2.4. Gonorrhoea
11.5.1.2.5. Trichomoniasis
11.5.1.2.6. Others
11.5.1.3. Market Value Forecast, by End-user, 2017–2031
11.5.1.3.1. Hospital
11.5.1.3.2. Diagnostic Centers
11.5.1.3.3. Others
11.5.2. South Africa
11.5.2.1. Market Value Forecast, by Type, 2017–2031
11.5.2.1.1. Direct Molecular DNA Probe
11.5.2.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
11.5.2.2. Market Value Forecast, by Application, 2017–2031
11.5.2.2.1. Bacterial Vaginosis
11.5.2.2.2. Vulvovaginal Candidiasis
11.5.2.2.3. Chlamydia
11.5.2.2.4. Gonorrhoea
11.5.2.2.5. Trichomoniasis
11.5.2.2.6. Others
11.5.2.3. Market Value Forecast, by End-user, 2017–2031
11.5.2.3.1. Hospital
11.5.2.3.2. Diagnostic Centers
11.5.2.3.3. Others
11.5.3. Rest of Middle East & Africa
11.5.3.1. Market Value Forecast, by Type, 2017–2031
11.5.3.1.1. Direct Molecular DNA Probe
11.5.3.1.2. Molecular Nucleic Acid Amplification Test (NAAT)
11.5.3.2. Market Value Forecast, By Application, 2017–2031
11.5.3.2.1. Bacterial Vaginosis
11.5.3.2.2. Vulvovaginal Candidiasis
11.5.3.2.3. Chlamydia
11.5.3.2.4. Gonorrhoea
11.5.3.2.5. Trichomoniasis
11.5.3.2.6. Others
11.5.3.3. Market Value Forecast, by End-user, 2017–2031
11.5.3.3.1. Hospital
11.5.3.3.2. Diagnostic Centers
11.5.3.3.3. Others
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country
12. Competition Landscape
12.1. Market Player - Competition Matrix (by tier and size of companies)
12.2. Company Profiles
12.2.1. Becton Dickenson
12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.1.2. Product Portfolio
12.2.1.3. SWOT Analysis
12.2.1.4. Strategic Overview
12.2.2. Atrida
12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2.2. Product Portfolio
12.2.2.3. SWOT Analysis
12.2.2.4. Strategic Overview
12.2.3. Hologic, Inc.
12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.3.2. Product Portfolio
12.2.3.3. SWOT Analysis
12.2.3.4. Strategic Overview
12.2.4. Quest Diagnostics Incorporated
12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.4.2. Product Portfolio
12.2.4.3. SWOT Analysis
12.2.4.4. Strategic Overview
12.2.5. Quidel Corporation
12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.5.2. Product Portfolio
12.2.5.3. SWOT Analysis
12.2.5.4. Strategic Overview
12.2.6. Mologic Ltd.
12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.6.2. Product Portfolio
12.2.6.3. SWOT Analysis
12.2.6.4. Strategic Overview
12.2.7. F. Hoffmann-La Roche Ltd.
12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.7.2. Product Portfolio
12.2.7.3. SWOT Analysis
12.2.7.4. Strategic Overview
12.2.8. QIAGEN
12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.8.2. Product Portfolio
12.2.8.3. SWOT Analysis
12.2.8.4. Strategic Overview
12.2.9. Abbott Laboratories
12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.9.2. Product Portfolio
12.2.9.3. SWOT Analysis
12.2.9.4. Strategic Overview
12.2.10. Cepheid (Danaher Corporation)
12.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.10.2. Product Portfolio
12.2.10.3. SWOT Analysis
12.2.10.4. Strategic Overview
12.2.11. Laboratory Corporation of America Holdings
12.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.11.2. Product Portfolio
12.2.11.3. SWOT Analysis
12.2.11.4. Strategic Overview
List of Table
Table 01: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 06: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 07: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 08: Germany Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 09: Germany Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 10: Germany Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 11: U.K. Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 12: U.K. Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 13: U.K. Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 14: France Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: France Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 16: France Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Italy Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 18: Italy Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 19: Italy Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Spain Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 21: Spain Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 22: Spain Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 23: Sweden Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 24: Sweden Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 25: Sweden Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 26: Denmark Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 27: Denmark Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 28: Denmark Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 29: Finland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 30: Finland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 31: Finland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 32: Austria Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 33: Austria Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 34: Austria Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 35: Switzerland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 36: Switzerland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 37: Switzerland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 38: Benelux Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 39: Benelux Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 40: Benelux Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 41: Norway Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 42: Norway Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 43: Norway Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 44: Poland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 45: Poland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 46: Poland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 47: Rest of Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 48: Rest of Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 49: Rest of Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 50: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 51: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 52: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 53: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 54: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 55: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 56: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 57: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 58: South Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 59: South Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 60: South Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 61: Rest of Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 62: Rest of Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figure
Figure 01: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: EMEA Vaginal Panel Testing Market Value Share, by Application, 2020
Figure 03: EMEA Vaginal Panel Testing Market Value Share, by Type, 2020
Figure 04: EMEA Vaginal Panel Testing Market Value Share, by End-user, 2020
Figure 05: EMEA Vaginal Panel Testing Market Value Share, by Region, 2020
Figure 06: EMEA Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 07: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 08: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Direct Molecular DNA Probe, 2017–2031
Figure 09: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Molecular Nucleic Acid Amplification Test (NAAT), 2017–2031
Figure 10: EMEA Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 11: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 12: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Bacterial Vaginosis, 2017–2031
Figure 13: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Vulvovaginal Candidiasis, 2017–2031
Figure 14: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Chlamydia, 2017–2031
Figure 15: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Gonorrhoea, 2017–2031
Figure 16: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Trichomoniasis, 2017–2031
Figure 17: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Others, 2017–2031
Figure 18: EMEA Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 19: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 19: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Others, 2017–2031
Figure 20: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 21: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Diagnostic Centers, 2017–2031
Figure 22: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Others, 2017–2031
Figure 23: EMEA Vaginal Panel Testing Market Analysis, 2020 and 2031
Figure 24: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by Region, 2021–2031
Figure 25: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 26: Europe Vaginal Panel Testing Market Value Share, by Country/Sub-region, 2020–2031
Figure 27: Europe Vaginal Panel Testing Market Attractiveness Analysis by Country/Sub-region, 2021–2031
Figure 28: Europe Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 29: Europe Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 30: Europe Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 31: Europe Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 32: Europe Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 33: Europe Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 34: Germany Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 35: Germany Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 36: Germany Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 37: Germany Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 38: Germany Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 39: Germany Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 40: U.K. Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 41: U.K. Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 42: U.K. Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 43: U.K. Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 44: U.K. Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 45: U.K. Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 46: France Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 47: France Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 48: France Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 49: France Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 50: France Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 51: France Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 52: Italy Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 53: Italy Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 54: Italy Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 55: Italy Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 56: Italy Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 57: Italy Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 58: Spain Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 59: Spain Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 60: Spain Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 61: Spain Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 62: Spain Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 63: Spain Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 64: Sweden Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 65: Sweden Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 66: Sweden Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 67: Sweden Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 68: Sweden Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 69: Sweden Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 70: Denmark Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 71: Denmark Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 72: Denmark Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 73: Denmark Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 74: Denmark Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 75: Breakdown of Net Sales (%), by Business Segment, 2020
Figure 75: Denmark Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 76: Breakdown of Net Sales (%), by Region, 2020
Figure 76: Finland Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 77: Finland Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 78: Finland Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 79: Finland Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 80: Finland Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 81: Finland Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 82: Austria Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 83: Austria Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 84: Austria Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 85: Austria Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 86: Austria Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 87: Austria Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 88: Switzerland Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 89: Switzerland Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 90: Switzerland Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 91: Switzerland Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 92: Switzerland Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 93: Switzerland Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 94: Benelux Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 95: Benelux Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 96: Benelux Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 97: Benelux Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 98: Benelux Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 99: Benelux Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 100: Norway Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 101: Norway Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 102: Norway Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 103: Norway Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 104: Norway Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 105: Norway Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 106: Poland Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 107: Poland Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 108: Poland Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 109: Poland Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 110: Poland Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 111: Rest of Europe Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 112: Rest of Europe Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 113: Rest of Europe Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 114: Rest of Europe Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 115: Rest of Europe Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 116: Rest of Europe Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 117: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 118: Middle East & Africa Vaginal Panel Testing Market Value Share, by Country/Sub-region, 2020–2031
Figure 119: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 120: Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 121: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 122: Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 123: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 124: Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 125: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 126: GCC Countries Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 127: GCC Countries Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 128: GCC Countries Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 129: GCC Countries Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 130: GCC Countries Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 131: GCC Countries Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 132: South Africa Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 133: South Africa Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 134: South Africa Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 135: South Africa Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 136: South Africa Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 137: South Africa Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 138: Rest of Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031
Figure 139: Rest of Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031
Figure 140: Rest of Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031
Figure 141: Rest of Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031
Figure 142: Rest of Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 143: Rest of Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 144: Vaginal Testing Panels Market Share, by Company, 2020
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Vaginal Panel Testing Market Trends, 2021-2031
